Redpoint Investment Management Pty Ltd grew its position in Johnson & Johnson (NYSE:JNJ) by 6.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,919 shares of the company’s stock after purchasing an additional 3,815 shares during the period. Johnson & Johnson makes up approximately 1.1% of Redpoint Investment Management Pty Ltd’s holdings, making the stock its 13th biggest position. Redpoint Investment Management Pty Ltd’s holdings in Johnson & Johnson were worth $10,689,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Morgan Stanley lifted its stake in shares of Johnson & Johnson by 4.3% in the 3rd quarter. Morgan Stanley now owns 22,472,765 shares of the company’s stock worth $3,345,745,000 after acquiring an additional 933,976 shares during the period. California Public Employees Retirement System lifted its stake in shares of Johnson & Johnson by 8.9% in the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after acquiring an additional 864,547 shares during the period. Boston Partners lifted its stake in shares of Johnson & Johnson by 16.1% in the 3rd quarter. Boston Partners now owns 6,862,037 shares of the company’s stock worth $1,021,620,000 after acquiring an additional 949,327 shares during the period. Ninety One UK Ltd lifted its stake in shares of Johnson & Johnson by 5.7% in the 3rd quarter. Ninety One UK Ltd now owns 5,827,983 shares of the company’s stock worth $867,670,000 after acquiring an additional 313,670 shares during the period. Finally, Raymond James & Associates lifted its stake in shares of Johnson & Johnson by 0.5% in the 3rd quarter. Raymond James & Associates now owns 3,688,170 shares of the company’s stock worth $549,100,000 after acquiring an additional 17,275 shares during the period. Hedge funds and other institutional investors own 61.26% of the company’s stock.

A number of analysts have recently weighed in on the stock. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Cantor Fitzgerald upped their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a research note on Tuesday, December 15th. BidaskClub raised shares of Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 6th. Finally, Credit Suisse Group increased their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $165.50.

Shares of NYSE:JNJ opened at $157.89 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The company has a market cap of $415.65 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.30 and a beta of 0.68. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $161.32. The firm has a 50 day simple moving average of $152.86 and a 200 day simple moving average of $148.31.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.12 EPS. On average, equities analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be paid a $1.01 dividend. The ex-dividend date is Monday, February 22nd. This represents a $4.04 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 54,662 shares of the company’s stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total value of $8,359,459.66. Following the transaction, the chief operating officer now owns 110,741 shares in the company, valued at approximately $16,935,621.13. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How to identify percentage decliners

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.